News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
331,658 Results
Type
Article (18002)
Company Profile (315)
Press Release (313334)
Multimedia
Podcasts (83)
Webinars (12)
Section
Business (91299)
Career Advice (268)
Deals (15386)
Drug Delivery (57)
Drug Development (54545)
Employer Resources (41)
FDA (6745)
Job Trends (6259)
News (164055)
Policy (12362)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (1222)
Accelerated approval (24)
Adcomms (14)
Allergies (91)
Alliances (26326)
ALS (137)
Alzheimer's disease (1252)
Antibody-drug conjugate (ADC) (260)
Approvals (6970)
Artificial intelligence (359)
Autoimmune disease (122)
Automation (21)
Bankruptcy (122)
Best Places to Work (5467)
BIOSECURE Act (10)
Biosimilars (119)
Biotechnology (238)
Bladder cancer (118)
Brain cancer (48)
Breast cancer (436)
Cancer (3640)
Cardiovascular disease (275)
Career advice (237)
Career pathing (12)
CAR-T (235)
CDC (9)
Cell therapy (618)
Cervical cancer (25)
Clinical research (47134)
Collaboration (1446)
Company closure (2)
Compensation (673)
Complete response letters (44)
COVID-19 (1310)
CRISPR (92)
C-suite (607)
Cystic fibrosis (115)
Data (4873)
Decentralized trials (1)
Denatured (15)
Depression (104)
Diabetes (312)
Diagnostics (2331)
Digital health (18)
Diversity (6)
Diversity, equity & inclusion (13)
Drug discovery (208)
Drug pricing (82)
Drug shortages (7)
Duchenne muscular dystrophy (217)
Earnings (35427)
Editorial (29)
Employer branding (5)
Employer resources (38)
Events (57776)
Executive appointments (697)
FDA (8838)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (23)
Funding (1141)
Gene editing (198)
Generative AI (32)
Gene therapy (529)
GLP-1 (590)
Government (1767)
Grass and pollen (4)
Guidances (209)
Healthcare (8713)
HIV (43)
Huntington's disease (44)
IgA nephropathy (79)
Immunology and inflammation (198)
Immuno-oncology (43)
Indications (72)
Infectious disease (1452)
Inflammatory bowel disease (162)
Inflation Reduction Act (12)
Influenza (53)
Intellectual property (180)
Interviews (41)
IPO (8378)
IRA (24)
Job creations (1093)
Job search strategy (194)
JPM (44)
Kidney cancer (10)
Labor market (26)
Layoffs (292)
Leadership (17)
Legal (1755)
Liver cancer (49)
Longevity (12)
Lung cancer (480)
Lymphoma (283)
Machine learning (31)
Management (13)
Manufacturing (455)
MASH (142)
Medical device (4016)
Medtech (4038)
Mergers & acquisitions (7733)
Metabolic disorders (844)
Multiple sclerosis (115)
NASH (13)
Neurodegenerative disease (259)
Neuropsychiatric disorders (77)
Neuroscience (2259)
Neurotech (1)
NextGen: Class of 2026 (2484)
Non-profit (1574)
Now hiring (33)
Obesity (382)
Opinion (162)
Ovarian cancer (143)
Pain (131)
Pancreatic cancer (178)
Parkinson's disease (256)
Partnered (17)
Patents (337)
Patient recruitment (395)
Peanut (46)
People (29445)
Pharmaceutical (50)
Pharmacy benefit managers (9)
Phase 1 (16430)
Phase 2 (21781)
Phase 3 (14106)
Pipeline (3751)
Policy (132)
Postmarket research (965)
Preclinical (6869)
Press Release (39)
Prostate cancer (172)
Psychedelics (51)
Radiopharmaceuticals (249)
Rare diseases (690)
Real estate (1829)
Recruiting (16)
Regulatory (11650)
Reports (23)
Research institute (1281)
Resumes & cover letters (31)
Rett syndrome (27)
RNA editing (21)
RSV (27)
Schizophrenia (127)
Series A (198)
Series B (147)
Service/supplier (1)
Sickle cell disease (81)
Special edition (19)
Spinal muscular atrophy (129)
Sponsored (20)
Startups (2270)
State (1)
Stomach cancer (5)
Supply chain (51)
Tariffs (31)
The Weekly (67)
Vaccines (485)
Venture capital (74)
Weight loss (203)
Women's health (35)
Worklife (3)
Date
Last 7 days (392)
Last 30 days (1348)
Last 365 days (20611)
2026 (1917)
2025 (20940)
2024 (23783)
2023 (25965)
2022 (31956)
2021 (33595)
2020 (28683)
2019 (19987)
2018 (14643)
2017 (16114)
2016 (14281)
2015 (16728)
2014 (11929)
2013 (8784)
2012 (8838)
2011 (8930)
2010 (8394)
Location
Africa (240)
Alabama (68)
Alaska (3)
Arizona (105)
Arkansas (9)
Asia (22196)
Australia (3788)
California (7935)
Canada (2092)
China (916)
Colorado (295)
Connecticut (296)
Delaware (263)
Europe (49988)
Florida (1014)
Georgia (234)
Hawaii (2)
Idaho (21)
Illinois (485)
India (48)
Indiana (207)
Iowa (11)
Japan (292)
Kansas (83)
Kentucky (11)
Louisiana (12)
Maine (47)
Maryland (847)
Massachusetts (6157)
Michigan (134)
Minnesota (308)
Mississippi (3)
Missouri (49)
Montana (17)
Nebraska (9)
Nevada (47)
New Hampshire (34)
New Jersey (1878)
New Mexico (15)
New York (1982)
North Carolina (940)
North Dakota (6)
Northern California (3938)
Ohio (201)
Oklahoma (15)
Oregon (26)
Pennsylvania (1443)
Puerto Rico (9)
Rhode Island (30)
South America (300)
South Carolina (10)
Southern California (3082)
Tennessee (72)
Texas (1189)
United States (26599)
Utah (115)
Virginia (159)
Washington D.C. (44)
Washington State (682)
West Virginia (2)
Wisconsin (67)
331,658 Results for "aim therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AIM ImmunoTech Announces Stock Dividend
December 30, 2025
·
2 min read
Press Releases
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
January 26, 2026
·
9 min read
Press Releases
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
January 28, 2026
·
7 min read
Mergers & acquisitions
J&J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash
Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ambitious goal for its oncology sales by 2030.
November 17, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror’
Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs.
January 21, 2026
·
2 min read
·
Dan Samorodnitsky
Press Releases
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
December 11, 2025
·
6 min read
Press Releases
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
December 2, 2025
·
1 min read
Press Releases
PathAI and University Hospital Zurich Announce Collaboration to Deploy AISight® Dx and AIM-TumorCellularity for Routine Molecular Pathology Workflows
January 8, 2026
·
3 min read
Press Releases
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments
September 17, 2025
·
3 min read
Press Releases
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
February 5, 2026
·
6 min read
1 of 33,166
Next
